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Abstract
Inflammation of the central nervous system is an important but poorly understood part of
neurological disease. After acute brain injury or infection there is a complex inflammatory response
that involves activation of microglia and astrocytes and increased production of cytokines,
chemokines, acute phase proteins, and complement factors. Antibodies and T lymphocytes may be
involved in the response as well. In neurodegenerative disease, where injury is more subtle but
consistent, the inflammatory response is continuous. The purpose of this prolonged response is
unclear, but it is likely that some of its components are beneficial and others are harmful. Animal
models of neurological disease can be used to dissect the specific role of individual mediators of
the inflammatory response and assess their potential benefit. To illustrate this approach, we discuss
how mutant mice expressing different levels of the cytokine transforming growth factor β-1 (TGF-
β1), a major modulator of inflammation, produce important neuroinflammatory phenotypes. We
then demonstrate how crosses of TGF-β1 mutant mice with mouse models of Alzheimer's disease
(AD) produced important new information on the role of inflammation in AD and on the
expression of different neuropathological phenotypes that characterize this disease.
Inflammatory profile of TGF-β1 mutant mice
TGF-β1 was initially described for its ability to transform
normal rat kidney cells [1]. Since then, it has been shown
to also promote cell survival or induce apoptosis, stimu-
late cell proliferation or induce differentiation, and initi-
ate or resolve inflammation. Its differential effects depend
on the cell type involved, the cell's environment, and the
duration and amount of TGF-β1 production. TGF-β recep-
tors are found on most cell types and their activation
affects the expression of a few hundred genes [2-4]. The
molecular aspects of TGF-β signalling are extensively stud-
ied and we refer to several excellent reviews [2,3]. In the
normal CNS, all three TGF-β isoforms and their receptors
are expressed within neurons, astrocytes, and microglia,
and TGF-β1 can modulate cellular responses in these cells
as well as in vascular and meningeal cells [5,6]. TGF-β1 is
the most abundant and best studied TGF-β isoform and
an important component of the brain's response to injury.
It is consistently increased after various forms of brain
insults and in neurodegenerative diseases (Table 1). Still,
we understand very little about the purpose and conse-
quences of increased TGF-β1 expression to brain function.
To study the role of TGF-β1 in the CNS we overproduced
bioactive peptide under the control of glial fibrillary
acidic protein (GFAP) regulatory sequences in astrocytes
of two independent lines of transgenic mice (herein called
TGF-β1 mice) [7]. We also analyzed brains of mice that are
TGF-β1 deficient or knockout [8]. C57BL/6 mice lacking
TGF-β1 have defects in vasculogenesis and angiogenesis
leading to early embryonic lethality [9,10], but mice on
the NIH genetic background survive up to 3–4 weeks of
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age before they succumb to an autoimmune wasting syn-
drome [11]. The effects of TGF-β1 expression and age on
the expression of inflammatory phenotypes in these mice
are graphically represented in what we call a "phenogram"
(Figure 1).
TGF-β1 overexpression at high levels results in 
hydrocephalus
Hydrocephalus and brain fibrosis are common sequelae
after whole brain inflammation due to bacterial meningi-
tis, subarachnoid hemorrhage, or severe traumatic brain
injury. High CSF levels of TGF-β1 in patients with sub-
arachnoid hemorrhage confer an increased risk of devel-
oping chronic hydrocephalus [12,13]. TGF-β1 injected
Table 1: TGF-β1 is elevated acutely after injury to the brain and chronically in neurodegenerative disease.
Injury/Insult or Disease Species Location/Cell type Timing Reference
Degenerative Disease
Alzheimer's Disease Human Entorhinal cortex and superior temporal 
gyrus mRNA; Brain microvessel, Senile 
plaques, neurofibrillary tangles, CSF 
protein
Chronic [48, 80, 82-84]
Vascular Dementia Human CSF protein Chronic [84]
Parkinson's Disease Human CSF dopaminergic striatal brain regions, 
protein
Chronic [85, 86]
Amyotrophic Lateral Sclerosis Human CSF and serum protein Chronic [87] [88]
Diabetic Neuropathy Human Plasma protein Chronic [89]
Acute Insult
Transient ischemia Rat Hippocampus/cerebellar protein; 
Hippocampal mRNA; Microglial mRNA 
and protein
20 min-12 weeks [90-92] [93, 94]
Permanent ischemia Human; rat; Baboon Increased mRNA in ischemic and 
penumbral areas
1–15 days [95-98]
Subarachnoid hemorrhage Human CSF protein 1–19 days [99]
Posthemorrhagic Hydrocephalus Human CSF protein 1–14 days [12, 13, 100]
Spinal cord injury Human Spinal cord mRNA 1–48 h [101]
Triethyltin exposure Mouse Cortical mRNA 6 hrs [102]
Excitotoxic lesion (NMDA) Rat Gray matter surrounding the lesion [103]
Status epilepticus Rat Hippocampal 1–3 weeks [104]
Kainic acid or deafferentation-induced 
neurodegeneration
Rat Reactive microglia, mRNA [105, 106]
Spinal cord Contusion Rat Spinal cord mRNA 0.25–10 days [107]
Penetrating brain Injury Rat Perilesional activated glia, meningeal 
cells, choroid plexus mRNA and protein
1–14 days [108, 109]
Experimentally induced glaucoma Monkey Optic nerve head protein Chronic [110]
Autoimmune Disease
Multiple Sclerosis Human CSF protein; Mononuclear cells from 
blood and CSF, mRNA; Serum protein 
during relapses; Peri-lesional 
hypertrophic astrocytes, protein
Chronic [111-114]
Chronic relapsing experimental 
autoimmune encephalitis
Mouse Spinal cord mRNA Chronic [115]
Experimental Autoimmune Encephalitis Rat Spinal cord T-cell, monocyte, and 
microglia mRNA
Acute [116]
Guillan-Barré Syndrome Human Serum and circulating monocyte protein Plateau phase [117, 118]




CMV encephalitis Human/mouse Astrocyte mRNA 5-13d after infection [120]
ME7 scrapie model Mouse Brain mRNA [121]
Bacterial Meningitis Rat Human CSF cellular mRNA CSF protein Brain 
mRNA, CSF protein
Acute [122-124]
Brain Abscess Human Peri-abscess and abscess extracellular 
matrix protein
Chronic [125]Journal of Neuroinflammation 2004, 1:10 http://www.jneuroinflammation.com/content/1/1/10
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into the lateral ventricles produces hydrocephalus in mice
[14]. TGF-β1 mice with high levels of expression in astro-
cytes had persistent communicating hydrocephalus at
birth, enlargement of cerebral hemispheres, and thinning
of the overlying cerebral cortex [7,15]. Additional stimu-
lation of the injury-responsive GFAP-TGF-β1 transgene in
adult low-expressor mice by CNS stab lesions leads to the
development of mild hydrocephalus. These results indi-
cate that hydrocephalus is directly related to TGF-β1
expression and not due to other developmental abnor-
malities [7]. Histological analysis shows decreased strati-
fication of neuronal cell layers and leukomalacia-like
areas. Given the extensive fibrosis of the meninges in TGF-
β1 mice hydrocephalus may be a result of decreased CSF
outflow through fibrotic arachnoid villi.
Indeed, TGF-β1 plays a key role in fibrosis in the lung
[16,17] and the kidney [18]. It induces the production of
a large number of extracellular matrix proteins, proteases
and their inhibitors [7,19] and it may be the excess pro-
duction of extracellular matrix proteins by TGF-β1 that
results in hydrocephalus. The amount of TGF-β1 pro-
duced in response to injury may vary among individuals
and be determined by genetic polymorphisms in the
TGFB1 gene. Polymorphisms that lead to higher levels of
TGF-β1 production in various assays were associated with
increased risk of fibrosis in transplant recipients [20] and
accelerated decline in lung function in patients with cystic
fibrosis [21].
TGF-β1 overexpression causes extensive cerebrovascular 
fibrosis
Studies in TGF-β1 knockout mice demonstrated an essen-
tial role for TGF-β1 in vasculogenesis and angiogenesis
during development [10] and other studies implicated
TGF-β1 also in maintaining vascular integrity in adults
[22,23]. Two TGF-β receptors on endothelial cells, endog-
lin and ALK1, mediate at least part of this effect and muta-
tions in these receptors cause genetic disorders of the
vasculature [24-26]. While low levels of TGF-β1 are neces-
sary for endothelial cell proliferation and angiogenesis,
higher levels result in increased synthesis of basement
membrane proteins and differentiation [27-29]. Our
results in TGF-β1 overexpressing mice are consistent with
these findings and implicate chronically elevated TGF-β1
levels directly in cerebrovascular fibrosis.
TGF-β1 mice demonstrated an age- and dose-dependent
formation of thioflavin S-positive perivascular amyloid
deposits and degeneration of vascular cells [30]. The amy-
loid deposits had an appearance similar to those found in
brains of AD cases with concomitant cerebral amyloid
angiopathy (CAA). However, Aβ, the proteolytic fragment
of human amyloid precursor protein (hAPP) that
accumulates in AD, was at best a minor component of the
deposits in TGF-β1 mice. Analysis of the progression of
the cerebrovascular changes in these mice showed a signif-
icant accumulation of basement membrane proteins per-
lecan and fibronectin in microvessels of 3–4-month-old
TGF-β1 mice. This change in the vasculature preceded the
formation of thioflavin S positive amyloid and was
Phenograms of TGF-β1 and hAPP/TGF-β1 mice Figure 1
Phenograms of TGF-β1 and hAPP/TGF-β1 mice. Underexpression and knockout of TGF-β1 results in neurodegenera-
tion. Overexpression of TGF-β1 in astrocytes produces phenotypes that are altered by the addition of a transgene expressing 
mutant human amyloid. TGF-β1-induced astrogliosis and microgliosis aid in clearing amyloid, and TGF-β1-induced vascular 
fibrosis traps amyloid in blood vessel walls, producing amyloid angiopathy.Journal of Neuroinflammation 2004, 1:10 http://www.jneuroinflammation.com/content/1/1/10
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accompanied by a thickening of the cortical capillary
basement membranes [30]. Vascular fibrosis occurs in
hypertension, in which TGF-β1 is elevated in serum of
patients [31], as well as in AD and vascular dementia,
both of which also are associated with increases in TGF-β1
(Table 1). We envision a scenario where TGF-β1 induces
extensive production and accumulation of extracellular
matrix proteins in the vascular wall resulting in the forma-
tion of β-pleated sheets, typically referred to as amyloid.
The deposition of amyloid in cerebral blood vessel walls
is the cause of CAA. It is a common vascular abnormality
in AD, where the amyloid contains large amounts of Aβ,
but it can occur in the nondemented elderly as well
[32,33]. CAA is a major cause of normotensive intracere-
bral haemorrhage [34]. It is also characterized by degener-
ation of cerebrovascular cell and thickening of the
vascular basement membrane [35-38].
TGF-β1 overproduction results in astrogliosis
Activation of astrocytes or astrogliosis is a prominent
component of the inflammatory response and an indica-
tor of injury in the brain. These astrocytes produce a large
array of inflammatory mediators, growth and neuropro-
tective factors, and they are involved in phagocytosis [39-
41]. Again, while some of these effects are clearly benefi-
cial, extensive astrogliosis may be detrimental and can
result in the formation of "glial scars" that prevent axonal
sprouting [42]. In TGF-β1 homozygous mice, GFAP and
TGF-β1 immunoreactivities were strongly elevated around
cerebral blood vessels, and activated astrocytes showed a
characteristic perivascular arrangement, a pattern often
observed in chronic hydrocephalus in humans and other
animals [43]. TGF-β1 mice with moderate or low levels of
TGF-β1 overexpression had a less pronounced astrogliosis
but GFAP expression was consistently increased [7].
Indeed, TGF-β1 directly increases GFAP transcription in
cultured astrocytes [44].
Microgliosis results from both increased and decreased levels of TGF-β1 Figure 2
Microgliosis results from both increased and decreased levels of TGF-β1. 30-month-old TGF-β1 mice (left panel) 
demonstrate increased staining for F4/80, a microglial marker, in the hippocampus. A stain for Iba1, which is present in all 
microglia and monocytes, reveals that microglia in TGF-β1 mice are more numerous and have more cytoplasm and shorter 
processes than microglia in an age-matched littermates. TGF-β1 knockout mice (right panel) demonstrate dramatically 
increased staining with F4/80 in all brain regions and Iba1staining reveals an activated microglial morphology that is less dra-
matic than that seen with TGF-β1 overexpression.Journal of Neuroinflammation 2004, 1:10 http://www.jneuroinflammation.com/content/1/1/10
Page 5 of 12
(page number not for citation purposes)
Either the absence or overproduction of TGF-β1 causes 
microgliosis
Activated microglia are also a typical part of the brain's
inflammatory response. Although TGF-β1 is generally
considered an anti-inflammatory cytokine, it has been
associated with recruitment of monocytes to the site of
injury at the beginning of the immune response [45]. Sim-
ilarly, TGF-β1 has been implicated in the activation and
recruitment of microglia and monocytes in HIV encepha-
litis [46]. Local expression of TGF-β1 in astrocytes also
renders transgenic mice more susceptible to experimental
autoimmune encephalomyelitis (EAE) [47], a rodent
model of multiple sclerosis. When challenged with spinal
cord homogenate, TGF-β1 mice show increased infiltra-
tion of monocyte/macrophage cells and increased expres-
sion of major histocompatibility complex (MHC) class II
proteins. These mice also develop a more severe clinical
phenotype and earlier onset of disease than nontransgenic
littermate controls [47]. TGF-β1 has also been shown to
induce expression of the proinflammatory cytokines
tumor necrosis factor (TNF)-α and IL-1β when added to
brain vascular endothelial cells [48]. Finally, TGF-β1 mice
demonstrate an age-related microgliosis that is most
prominent in the hippocampus (Figure 2). Preliminary
studies suggest that this microgliosis is associated with
reduced neurogenesis (Buckwalter and Wyss-Coray
unpublished data).
Consistent with TGF-β1's anti-inflammatory role, knock-
out mice showed a striking microgliosis in the neocortex
and hippocampus at P1 and even more so at P21 (Figure
2). Interestingly, no concomitant increase in astrocyte
activation was observed in TGF-β1 knockout mice [8]. As
mentioned above, overexpression of TGF-β1 using adeno-
virus led to decreased production of the inflammatory
chemokines MCP-1 and Mip-1α after transient cerebral
ischemia [49]. These effects of TGF-β1 on the recruitment
and activation of microglial cells and inflammatory
responses in the CNS in general may be of importance not
only for classical immune-mediated CNS diseases such as
MS and HIV encephalitis, but also for other CNS diseases
with an involvement of microglia and inflammatory
responses, notably AD (see below).
Increased TGF-β1 is neuroprotective and decreased TGF-
β1 leads to neurodegeneration
TGF-β1 has been demonstrated to protect neurons against
various toxins and injurious agents in cell culture and in
vivo (reviewed in [5,50]). For example, intracarotid infu-
sion of TGF-β1 in rabbits reduces cerebral infarct size
when given at the time of ischemia [51]. Rat studies also
showed that TGF-β1 protects hippocampal neurons from
death when given intrahippocampally or intraventricu-
larly one hour prior to transient global ischemia [52].
Mice infected with adenovirus that overexpressed TGF-β1
five days prior to transient ischemia also had smaller inf-
arctions than control animals [49]. Astroglial overexpres-
sion of TGF-β1 in transgenic mice protects against
neurodegeneration induced with the acute neurotoxin
kainic acid or associated with chronic lack of apolipopro-
tein E expression [8]. Boche and coworkers also demon-
strated that TGF-β1 protects neurons from excitotoxic
death [53]. In contrast, TGF-β1 knockout mice display
signs of spontaneous neuronal death, with prominent
clusters of TUNEL-positive cells in different parts of the
brain including the neocortex, caudate putamen and cere-
bellum [8]. Besides the increase in TUNEL-positive neu-
rons, unmanipulated 3-week-old TGF-β1 knockout mice
also have significantly fewer synaptophysin positive syn-
apses in the neocortex and hippocampus compared to
wildtype littermate controls, and increased susceptibility
to kainic acid-induced neurotoxicity.
It is not clear how TGF-β1 protects neurons, but several
mechanisms have been postulated. For example, TGF-β1
decreases Bad, a pro-apoptotic member of the Bcl-2 fam-
ily, and contributes to the phosphorylation, and thus
inactivation, of Bad by activation of the Erk/MAP kinase
pathway [54]. On the other hand, TGF-β1 increases pro-
duction of the anti-apoptotic protein Bcl-2 [55]. TGF-β1
has also been shown to synergize with neurotrophins
and/or be necessary for at least some of the effects of a
number of important growth factors for neurons, includ-
ing neurotrophins, fibroblast growth factor-2, and glial
cell-line derived neurotrophic factor (reviewed in
[50,56]). In addition, TGF-β1 increases laminin expres-
sion [7] and is necessary for normal laminin protein levels
in the brain [8]. Laminin is thought to provide critical
support for neuronal differentiation and survival and may
be important for learning and memory [57,58]. It is also
possible that TGF-β1 decreases inflammation in the inf-
arction area, attenuating secondary neuronal damage
[49].
In addition to its effects on neuronal maintenance and
survival, TGF-βs and the TGF-β signalling pathway have
recently been implicated in the regulation of synaptic
growth and function (reviewed in [59]). Synaptic over-
growth is caused by abnormal TGF-β signalling in Dro-
sophila  with mutations in genes encoding for the late
endosomal gene spinster whereas the inhibitory Smad pro-
tein Dad, and mutations in TGF-β receptors can prevent
this phenotype [60]. TGF-β receptors and dSmad2 are also
required for neuronal remodelling in the Drosophila brain
[61]. In Aplysia, sensory neurons express a type II TGF-β
receptor and recombinant human TGF-β1 induces phos-
phorylation and redistribution of the presynaptic protein
synapsin and modulates synaptic function [62,63]. Thus,
TGF-β signals may be important in modulating synaptic
strength and numbers in mammals as well.Journal of Neuroinflammation 2004, 1:10 http://www.jneuroinflammation.com/content/1/1/10
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Modulation of the neuroinflammatory profile in 
Alzheimer's models
Neuroinflammation is a prominent characteristic of neu-
rodegenerative diseases like AD and is likely to encompass
beneficial and detrimental effects [39]. Thus, inflamma-
tory processes may attempt to clear dying cells or aggre-
gated proteins, initiate repair processes, but also
contribute to cell death and degeneration. The neuroin-
flammatory profile of AD as observed by a neuropatholo-
gist does not allow him to draw conclusions about
mechanisms, sequence of action, or cause and effect of
any of the mediators involved. Therefore, inflammatory
processes in the AD brain need to be studied in appropri-
ate model systems in order to understand their roles in the
disease process.
AD is characterized clinically by an age-dependent pro-
gressive cognitive decline and pathologically by the pres-
ence of protein deposits in the form of amyloid plaques
and cerebrovascular Aβ deposits in the extracellular space.
In addition, abnormal phosphorylation of the
microtubule associated protein tau results in the forma-
tion of tangles inside neurons [64]. These protein deposits
are associated with prominent neurodegeneration and
neuroinflammation. There is strong evidence that abnor-
mal production or accumulation of Aβ is a key factor in
the pathogenesis of AD (reviewed in [65]) but many
cofactors are likely to modulate Aβ toxicity. Transgenic
mouse models overproducing familial AD-mutant hAPP
reproduce important aspects of AD, including amyloid
plaques, neurodegeneration, neuroinflammation, and
cognitive deficits (for example [66-68]). Specific inflam-
matory mediators can be studied in these AD models by
crossing them with mice lacking or overproducing
selected inflammatory mediators. The phenogram of TGF-
β1 mutant mice (Figure 1) illustrates and underlines the
prominent effects this cytokine has on inflammatory
processes in the brain. Altering TGF-β1 levels could there-
fore be expected to have prominent effects on the neu-
roinflammatory profile of AD.
TGF-β1 overexpression in AD mice results in CAA
Overexpression of TGF-β1 in hAPP mice resulted in a dra-
matic shift in the site of Aβ accumulation (Figure 3).
While Aβ accumulates almost exclusively in parenchymal
plaques in hAPP mice, most of the Aβ is associated with
vascular structures in hAPP/TGF-β1 bigenic mice at 12–15
months of age. These vascular deposits in bigenic mice are
already detectable at 2–3 months of age with human Aβ
specific antibodies, whereas age-matched singly trans-
genic hAPP or TGF-β1 control mice have no such deposits
[69]. This mechanism of vascular amyloid formation may
be relevant for humans as well. Cortical TGF-β1 mRNA
levels correlate positively with the degree of cerebrovascu-
lar amyloid deposition in AD patients, and analysis of
mildly fixed cortical tissues showed that TGF-β1 immuno-
reactivity was elevated along cerebral blood vessels and in
perivascular astrocytes [69,70]. An increase in TGF-β1
may be triggered in response to traumatic brain injury or
other forms of neuronal and cellular injury. Interestingly,
brain injury is considered a major environmental risk fac-
tor for AD [71], and in traumatic brain injury, blood-
derived TGF-β1 stored in platelets is likely released in
large amounts at the lesion site [19]. In addition, individ-
uals with a predisposition to higher TGF-β1 production,
particularly in response to injury, may be more suscepti-
ble to vascular variants of AD.
How does TGF-β1 cause such a dramatic change in the site
of Aβ deposition? As alluded to above, TGF-β1 induces
the production of many extracellular matrix proteins in
the vascular basement membrane. Proteins including
laminin, fibronectin, and heparan sulfate proteoglycans
(HSPG) such as perlecan, have been implicated in amy-
loidosis (reviewed in [72,73]. In particular, glu-
cosaminoglycan side chains of HSPGs can precipitate Aβ
injected into the brain [74]. It is therefore likely that TGF-
β1-induced basement membrane accumulation and
fibrosis precipitates the accumulation of Aβ. In several dif-
ferent cell culture systems, TGF-β1 can also directly induce
the expression of the APP gene [75-77]. There is currently
one drug, made by Neurochem (Montreal, Quebec, Can-
ada), which has completed phase clinical II trials that
reduces amyloid deposition in transgenic mouse models
by interfering with the interaction between Aβ and
glucosaminoglycans.
TGF-β1-induced gliosis and amyloid clearance
Besides the accumulation of Aβ in the vasculature, bigenic
hAPP/TGF-β1 mice have a 75% reduction in parenchymal
amyloid plaques and overall levels of Aβ are 60–70%
lower than in singly transgenic hAPP littermate controls
[69]. Similar to singly-transgenic TGF-β1 mice, increased
astroglial TGF-β1 production in aged bigenic mice causes
extensive microglial and astroglial activation in the hip-
pocampus and cortex [69]. Both cell types are phagocytic
and we demonstrated that activation of cultured microglia
with TGF-β1 results in increased degradation of Aβ [69].
In addition, primary adult astrocytes phagocytose Aβ
bound to plastic or in brain sections from hAPP mice [40].
Thus, while fibrosis due to overexpression of TGF-β1
probably directs the deposition of Aβ to vascular walls,
TGF-β1-activated microglia and/or astrocytes can degrade
Aβ and lower brain concentration of Aβ overall (Figure 3).
In AD patients, Aβ accumulation in parenchymal plaques
seems to correlate inversely with Aβ in cerebral blood ves-
sels [69,78,79] and it is tempting to speculate that TGF-β1
is involved in this process.Journal of Neuroinflammation 2004, 1:10 http://www.jneuroinflammation.com/content/1/1/10
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TGF-β1-induced neuroprotection
Given the large number of studies demonstrating that
TGF-β1 is neuroprotective, it is reasonable to assume that
one of the roles of TGF-β1 is to keep neurons alive in the
brains of patients with Alzheimer's Disease. Indeed,
expression of TGF-β1 in the superior temporal gyrus of AD
brains correlates inversely with neurofibrillary tangle
counts but is increased only in the late stages of disease
TGF-β1 overexpression in hAPP mice leads to CAA and reduces total brain amyloid Figure 3
TGF-β1 overexpression in hAPP mice leads to CAA and reduces total brain amyloid. hAPP mice demonstrate 
amyloid plaques that are predominantly parenchymal (left panels), while bigenic hAPP/TGF-β1 mice (right panels) display fewer 
parenchymal amyloid plaques and have Aβ deposits localized to blood vessel walls (Aβ, green; Glut-1, red).Journal of Neuroinflammation 2004, 1:10 http://www.jneuroinflammation.com/content/1/1/10
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[80]. hAPP/TGF-β1 mice have fewer dystrophic neurites
than hAPP controls but this is likely confounded by the
decrease in amyloid deposition in these mice [69]. Nota-
bly, TGF-β1 overproduction results not only in an overall
decrease in Aβ accumulation in hAPP/TGF-β1 brains but
also in a relative decrease in Aβ1–42 out of the total Aβ
pool. The relative amount of Aβ1–42 appears to be a good
measure for the relative toxicity and propensity of Aβ to
aggregate. Chronic TGF-β1 production is likely to have
different effects than acutely induced TGF-β1 and this
could also have detrimental effects on neuronal survival.
For example, vascular fibrosis could cause ischemia and
make areas with high TGF-β1 levels more susceptible to
neuronal death. Interestingly, old TGF-β1 mice have
decreased blood flow to the hippocampus that correlates
inversely with the thioflavin-S positive vascular deposits
in this region [81]. Better tools will be necessary to sepa-
rate direct neuroprotective from indirect effects of TGF-β1
in vivo.
Conclusions
Neuroinflammation occurs consistently in neurological
diseases but its role is unclear. We demonstrate here that
the analysis of inflammatory phenotypes in TGF-β1 mice
has been helpful in understanding human disease. First,
highly elevated cerebral TGF-β1 production is clearly asso-
ciated with hydrocephalus in mice and humans. Interfer-
ing with local production of TGF-β1 may therefore be of
potential therapeutic value in the management of hydro-
cephalus. Second, studying chronic overproduction of
TGF-β1 in a mouse model for AD revealed that TGF-β1
has a key role in the development of CAA and also reduces
amyloid deposition in the parenchyma. This highlights
the utility of such models in dissecting opposing effects of
inflammatory mediators in neurological diseases. Thera-
peutic approaches blocking the effect of TGF-β1 on the
vasculature or promoting TGF-β1's effect in the brain
parenchyma can be pursued based on these results. In fact,
a drug that interferes with the accumulation of Aβ in the
basement membrane has now completed phase II clinical
trials.
Despite the progress made in understanding the role of
TGF-β1 and many other factors in inflammation, many
questions remain. Animal models such as Drosophila
might be useful to study simple aspects of inflammation
such as phagocytosis, but more complex inflammatory
pathways are absent in flies and need to be studied in
mammals.  Drosophila  could also be used to study the
direct effects of cytokines on neurons and glial cells [59].
New genomic and proteomic approaches will be helpful
in expanding our understanding of neuroinflammation in
animal models to more complex levels. This will also
require mathematical modelling systems as well as power-
ful database tools. Importantly, the inflammatory pheno-
types generated in animal models need to be linked to
functional outcome measures because these are the only




Aβ1–42 A-beta peptide containing amino acids 1–42
AD Alzheimer's disease
CAA Cerebral amyloid angiopathy
CNS Central nervous system
CSF Cerebrospinal fluid
EAE Experimental autoimmune encephalomyelitis
GFAP Glial fibrillary acidic protein
hAPP human amyloid precursor protein
HIV Human immunodeficieny virus
HSPG Heparan sulfate proteoglycan
Iba-1 Ionized calcium-binding adaptor molecule-1
Il-1β Interleukin-1β
MAP Mitogen activated protein
MCP-1 Monocyte chemoattractant protein-1
MHC Major histocompatability complex
Mip-1α Macrophage inflammatory protein-1 alpha
MS Multiple sclerosis
NIH National Institutes of Health
P1 Postnatal day 1
P21 Postnatal day 21
TGF-β Transforming growth factor-beta
TNF-α Tumor necrosis factor alpha
TUNEL Terminal deoxynucleotidyl transferase dUTP-
biotin nick-end labellingJournal of Neuroinflammation 2004, 1:10 http://www.jneuroinflammation.com/content/1/1/10
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